Updates are available Correction dated 2024-09-10
Click to view Correction: https://doi.org/10.1007/s00125-024-06278-2
-
Authors
Galindo, Rodolfo J. https://orcid.org/0000-0002-9295-3225
Soliman, Diana https://orcid.org/0000-0003-0696-2377
Cherñavvsky, Daniel https://orcid.org/0000-0001-7395-1841
Rhee, Connie M. https://orcid.org/0000-0002-9703-6469
-
Funding
Funding for this research was provided by:
NIDDK to RJG (1K23DK123384-5, 1R03DK138255-1, P30DK111024-8, U2CDK137135)
- License Information
-
More Information
Article History
Received: 29 April 2024
Accepted: 3 July 2024
First Online: 8 August 2024
Change Date: 10 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00125-024-06278-2
Acknowledgements
: We would like to thank G. Arevalo, postdoctoral fellow in the Division of Endocrinology at the University of Miami, for her invaluable editorial support.
: RJG is supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under award numbers P30DK111024-8, 1K23DK123384-5, U2CDK137135 and 1R03DK138255-1.
: RJG has received research support from Novo Nordisk, Eli Lilly and Dexcom, and consulting/advisory/honoraria fees from Abbott Diabetes, AsztraZeneca, Bayer, Boehringer, Dexcom, Eli Lilly, Novo Nordisk and Medtronic. DC is a former employee of Dexcom and holds stocks. CMR has received honoraria/funding from AstraZeneca, Dexcom, Fresenius and Vifor. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published.
